BG Medicine's heart failure Dx wins higher CMS coverage; Blood test to screen for presymptomatic Alzheimer's advances;

> BG Medicine's ($BGMD) stock price doubled Dec. 10 after the Centers for Medicare and Medicaid Services nearly doubled the reimbursement price for the company's test that allows for early detection of chronic heart failure. Story

> King's College London researchers said they've made major progress on a blood test that could screen for Alzheimer's before clinical symptoms appear. Story

> Navidea Biopharmaceuticals ($NAVB) won special designation from the FDA to expedite a supplemental new drug application to use Lymphoseek injection to help map lymph nodes in patients with head and neck cancer. Item

> Bermuda's Health Ministry is considering rules that would require precertification before patients can undergo medical diagnostic procedures. Story

> Home diagnostic testing devices could help monitor epilepsy drug levels, according to two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington, D.C. Item

> Viracor-IBT, a specialty diagnostics lab focused on immunology, infectious disease and allergy testing, has snatched up the National Institute of Transplantation's Los Angeles-based serology and HLA laboratory operations. Story

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.